Top Markets
#1 Resolv wstUSR Resolv wstUSR +114.56%
#2 Luxxcoin Luxxcoin +46.85%
#3 Layer3 Layer3 +32.82%
#4 ResearchCoin ResearchCoin +31.78%
#5 Reactive Network Reactive Network +24.01%
#6 Orderly Network Orderly Network +17.27%
#7 Bitgert Bitgert +17.01%
#8 Lisk Bridged wstETH (Lisk) Lisk Bridged wstETH (Lisk) +10.20%
#9 Useless Coin Useless Coin +10.11%
#10 OpenVPP OpenVPP +9.68%
Coin of the day
Resolv wstUSR Resolv wstUSR
Settings
Language
ENGLISH
Currency
USD
Theme
CSL Limited CSL Limited

CSL Limited

CSL
Rank in Stocks #432
CSL Limited researches, develops, manufactures, markets, and distributes... CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
Share Price
$99.32
Market Cap
$48.20B
Change (1 day)
0.98%
Change (1 year)
-32.14%
Country
AU
Trade CSL Limited (CSL)

Category

Healthcare
Number of shares outstanding for CSL Limited (CSL)
Number of shares outstanding as of December 2025: 483.58M
According to CSL Limited latest financial reports and stock price the company's current number of shares outstanding is 483.58M. At the end of June 2024 the company had 483.01M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for CSL Limited (CSL) from 2000 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
2026 (TTM) 483.58M -0.06%
2025 483.88M 0.18%
2024 483.01M 0.17%
2023 482.17M 2.86%
2022 468.76M 3.05%
2021 454.87M 0.23%
2020 453.81M 0.20%
2019 452.92M 0.13%
2018 452.35M -0.65%
2017 455.33M -1.44%
2016 462.00M -2.08%
2015 471.82M -2.48%
2014 483.82M -2.97%
2013 498.61M -3.97%
2012 519.23M -3.94%
2011 540.53M -4.63%
2010 566.78M -4.78%
2009 595.24M 8.21%
2008 550.11M 0.44%
2007 547.71M 0.30%
2006 546.08M -7.12%
2005 587.97M 10.00%
2004 534.52M 11.94%
2003 477.51M 0.53%
2002 474.99M 5.89%
2001 448.57M 12.11%
2000 400.11M 0.00%
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 4.45B 819.78%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -47.50%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 102.90M -78.72%
US
UCB SA UCB SA
UCB SA
UCB.BR
 190.00M -60.71%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 61.42M -87.30%
NL